Facebook
X
LinkedIn
Forward
Androgen Deprivation Therapy and Dose Escalation for Prostate Cancer: Lessons from Randomized Trials and the MARCAP Consortium
Numerous randomized trials have studied the benefit of adding androgen deprivation therapy (ADT) and/or prolonging its duration when treating localized prostate cancer with radiotherapy, while other trials have interrogated the benefit of escalating radiotherapy dose itself. These trials have varied considerably in the sequencing of ADT that was used. Based on the successes of individual patient data meta-analyses in quantifying the benefit of adding postoperative radiotherapy for breast cancer patients and determining the optimal sequencing of chemotherapy and radiation for head and neck cancer patients, the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium was founded to better quantify the benefits of dose escalation and ADT use, duration, and sequencing. The MARCAP Consortium additionally provided information to evaluate the kinetics of testosterone recovery after ADT and potential oncologic implications, as well as the clinical importance of various endpoints after definitive treatment. This educational activity highlights and summarizes completed, ongoing, and future work from the MARCAP consortium with a focus on implications for contemporary practice. Specifically, we: (a) provide data to quantify the benefits of ADT use and prolongation as well as the benefits of dose escalation, (b) evaluate and identify the optimal sequencing of ADT with radiotherapy, (c) discuss testosterone recovery after ADT and implications for treatment outcome, and (d) discuss the endpoint of biochemical recurrence and its clinical and practical significance.
Topics:
- ADT and Dose-Escalation for Prostate Cancer: Lessons from Randomized Trials and the MARCAP Consortium
Daniel E. Spratt, MD - Sequencing Short-Term Hormonal Therapy With Radiotherapy for Prostate Cancer: What is Best?
T. Martin Ma, MD, PhD - The Kinetics of Testosterone Recovery After Androgen Deprivation Therapy: Implications for Outcomes
Wee Loon Ong, MBBS - Endpoints in Localized Prostate Cancer: Clinical Importance
Angela Y. Jia, MD, PhD - Q and A
Amar U. Kishan, MD – Moderator
Full Panel
This activity is available from February 17, 2026, through 11:59 p.m. Eastern time on February 16, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Quantify the benefits of adding hormonal therapy versus increasing radiation for the definitive management of localized prostate cancer.
- Discuss the oncological impact of varying the sequencing of androgen deprivation therapy with radiation, as well as the kinetics of testosterone recovery.
- Discuss key oncologic endpoints and their significance for patients treated with radiotherapy for prostate cancer.
Moderator:
- Amar U. Kishan, MD, is employed by University of California, Los Angeles. Dr. Kishan receives grant/research funding from Boston Scientific, Janssen, Inc., Point BioPharma and Lantheus. Dr. Kishan receives honoraria from Boston Scientific, Lantheus and Varian Medical Systems. Dr. Kishan owns stock in ViewRay.
Speakers:
- Daniel E. Spratt, MD, is employed by University Hospitals Seidman Cancer Center, Case Western Reserve University. Dr. Spratt receives honoraria from Astellas, Bayer, Boston Scientific, GSK, Janssen, Novartis and Myovant/Pfizer.
- T. Martin Ma, MD, PhD, is employed by University of Washington – Fred Hutchinson Cancer Center. Dr. Ma has no relevant financial relationship with ineligible companies to disclose.
- Wee Loon Ong, MBBS, is employed by Monash University. Dr. Ong has no relevant financial relationship with ineligible companies to disclose.
- Angela Y. Jia, MD, PhD, is employed by University Hospitals Seidman Cancer Center, Case Western Reserve University. Dr. Jia has no relevant financial relationship with ineligible companies to disclose.
Planners:
- Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until February 16, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.